{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T12:09:21Z","timestamp":1771502961269,"version":"3.50.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T00:00:00Z","timestamp":1556236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K23 AI097234"],"award-info":[{"award-number":["K23 AI097234"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K24 HL093294"],"award-info":[{"award-number":["K24 HL093294"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["CA15704"],"award-info":[{"award-number":["CA15704"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["272201600019C-3-0-1"],"award-info":[{"award-number":["272201600019C-3-0-1"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The differential impact of preemptive therapy (PET) and antiviral prophylaxis (AP) on development of cytomegalovirus (CMV)\u2013specific neutralizing antibody (nAb) and T-cell responses have not previously been directly compared in high-risk donor-seropositive\/recipient-seronegative (D+R\u2212) organ transplant recipients. We prospectively assessed T-cell and nAb responses 3 months after transplantation in cohorts of high-risk D+R\u2212 liver transplant recipients who received either PET (n = 15) or AP (n = 25) and a control group of CMV-seropositive transplant recipients (R+) (AP; n = 24). CMV phosphoprotein 65 (pp65)\u2013 and immediate early protein 1\u2013specific multifunctional T-cell responses were determined by means of intracellular cytokine staining and nAbs against BADrUL131-Y4 CMV in adult retinal pigment epithelial cell line-19 human epithelial cells; nAbs were detected in 8 of 12 (67%) in the PET group, none of 17 in the AP group, and 20 of 22 (91%) in the R+ group. Multifunctional CD8 and CD4 T-cell responses to pp65 were generally similar between PET and R+ groups, and lower for the AP group; multifunctional CD4 responses were similar across all groups. Among D+R\u2212 liver transplant recipients, PET was associated with the development of greater nAb and multifunctional CD8 T-cell responses compared with AP, providing a potential mechanism to explain the relative protection against late-onset disease with PET. Future studies are needed to define specific immune parameters predictive of late-onset CMV disease with AP.<\/jats:p>","DOI":"10.1093\/infdis\/jiz181","type":"journal-article","created":{"date-parts":[[2019,4,22]],"date-time":"2019-04-22T19:13:58Z","timestamp":1555960438000},"page":"752-760","source":"Crossref","is-referenced-by-count":34,"title":["Prospective Assessment of Cytomegalovirus Immunity in High-Risk Donor-Seropositive\/Recipient-Seronegative Liver Transplant Recipients Receiving Either Preemptive Therapy or Antiviral Prophylaxis"],"prefix":"10.1093","volume":"220","author":[{"given":"Ajit P","family":"Limaye","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret L","family":"Green","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle"},{"name":"Fred Hutchinson Cancer Research Center, Seattle"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley C","family":"Edmison","sequence":"first","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry","family":"Stevens-Ayers","sequence":"first","affiliation":[{"name":"Program in Infectious Diseases, VA Pittsburgh Healthcare System and University of Pittsburgh, Pennsylvania"},{"name":"Fred Hutchinson Cancer Research Center, Seattle"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam","family":"Chatterton-Kirchmeier","sequence":"first","affiliation":[{"name":"Program in Infectious Diseases, VA Pittsburgh Healthcare System and University of Pittsburgh, Pennsylvania"},{"name":"Fred Hutchinson Cancer Research Center, Seattle"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam P","family":"Geballe","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle"},{"name":"Program in Infectious Diseases, VA Pittsburgh Healthcare System and University of Pittsburgh, Pennsylvania"},{"name":"Fred Hutchinson Cancer Research Center, Seattle"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Singh","sequence":"first","affiliation":[{"name":"Program in Infectious Diseases, VA Pittsburgh Healthcare System and University of Pittsburgh, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Boeckh","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle"},{"name":"Program in Infectious Diseases, VA Pittsburgh Healthcare System and University of Pittsburgh, Pennsylvania"},{"name":"Fred Hutchinson Cancer Research Center, Seattle"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,4,26]]},"reference":[{"key":"2020063006340278800_CIT0001","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1600-6143.2008.02191.x","article-title":"Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation","volume":"8","author":"Mattes","year":"2008","journal-title":"Am J Transplant"},{"key":"2020063006340278800_CIT0002","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1111\/j.1600-6143.2008.02425.x","article-title":"Polyfunctional cytomegalovirus-specific CD4+ and pp65 CD8+ T cells protect against high-level replication after liver transplantation","volume":"8","author":"Nebbia","year":"2008","journal-title":"Am J Transplant"},{"key":"2020063006340278800_CIT0003","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0140-6736(11)60136-0","article-title":"Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial","volume":"377","author":"Griffiths","year":"2011","journal-title":"Lancet"},{"key":"2020063006340278800_CIT0004","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01794-16","article-title":"Phase 2 randomized, double-blind, placebo-controlled trial of RG7667, a combination monoclonal antibody, for prevention of cytomegalovirus infection in high-risk kidney transplant recipients","volume":"61","author":"Ishida","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020063006340278800_CIT0005","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1099\/jgv.0.000882","article-title":"The pentameric complex of human cytomegalovirus: cell tropism, virus dissemination, immune response and vaccine development","volume":"98","author":"Gerna","year":"2017","journal-title":"J Gen Virol"},{"key":"2020063006340278800_CIT0006","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1007\/s10875-012-9739-3","article-title":"Antibodies against neutralization epitopes of human cytomegalovirus gH\/gL\/pUL128-130-131 complex and virus spreading may correlate with virus control in vivo","volume":"32","author":"Lilleri","year":"2012","journal-title":"J Clin Immunol"},{"key":"2020063006340278800_CIT0007","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1056\/NEJM198710223171703","article-title":"Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients","volume":"317","author":"Snydman","year":"1987","journal-title":"N Engl J Med"},{"key":"2020063006340278800_CIT0008","doi-asserted-by":"crossref","first-page":"ofz003","DOI":"10.1093\/ofid\/ofz003","article-title":"Correlation of cytomegalovirus (CMV) disease severity and mortality with CMV viral burden in CMV-seropositive donor and CMV-seronegative solid organ transplant recipients","volume":"6","author":"McBride","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2020063006340278800_CIT0009","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1073\/pnas.1814835116","article-title":"HCMV trimer- and pentamer-specific antibodies synergize for virus neutralization but do not correlate with congenital transmission","volume":"116","author":"Vanarsdall","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020063006340278800_CIT0010","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.1073\/pnas.1800224115","article-title":"Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies","volume":"115","author":"Baraniak","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020063006340278800_CIT0011","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1086\/319225","article-title":"Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients","volume":"32","author":"Singh","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2020063006340278800_CIT0012","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1086\/427506","article-title":"Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: a call to heed the mounting evidence","volume":"40","author":"Singh","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2020063006340278800_CIT0013","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/lt.21362","article-title":"Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts","volume":"14","author":"Singh","year":"2008","journal-title":"Liver Transpl"},{"key":"2020063006340278800_CIT0014","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2020063006340278800_CIT0015","doi-asserted-by":"crossref","first-page":"10330","DOI":"10.1128\/JVI.79.16.10330-10338.2005","article-title":"Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism","volume":"79","author":"Wang","year":"2005","journal-title":"J Virol"},{"key":"2020063006340278800_CIT0016","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1016\/j.vaccine.2008.07.092","article-title":"Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection","volume":"26","author":"Cui","year":"2008","journal-title":"Vaccine"},{"key":"2020063006340278800_CIT0017","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1111\/ajt.14672","article-title":"CMV-infected kidney grafts drive the expansion of blood-borne CMV-specific T cells restricted by shared class I HLA molecules via presentation on donor cells","volume":"18","author":"Gatault","year":"2018","journal-title":"Am J Transplant"},{"key":"2020063006340278800_CIT0018","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcv.2018.06.009","article-title":"T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients","volume":"105","author":"Gliga","year":"2018","journal-title":"J Clin Virol"},{"key":"2020063006340278800_CIT0019","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1093\/infdis\/jiy592","article-title":"The ability of a cytomegalovirus ELISPOT assay to predict outcome of low-level CMV reactivation in hematopoietic cell transplant recipients","volume":"219","author":"El Haddad","year":"2019","journal-title":"J Infect Dis"},{"key":"2020063006340278800_CIT0020","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1099\/vir.0.000203","article-title":"Role of cytomegalovirus (CMV)-specific polyfunctional CD8+ T-cells and antibodies neutralizing virus epithelial infection in the control of CMV infection in an allogeneic stem-cell transplantation setting","volume":"96","author":"Gim\u00e9nez","year":"2015","journal-title":"J Gen Virol"},{"key":"2020063006340278800_CIT0021","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1128\/CVI.05128-11","article-title":"Neutralizing activity of saliva against cytomegalovirus","volume":"18","author":"Saccoccio","year":"2011","journal-title":"Clin Vaccine Immunol"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiz181\/28679950\/jiz181.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/220\/5\/752\/33445914\/jiz181.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/220\/5\/752\/33445914\/jiz181.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T10:34:16Z","timestamp":1593513256000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/220\/5\/752\/5480166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,26]]},"references-count":21,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,4,26]]},"published-print":{"date-parts":[[2019,7,31]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiz181","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,9,1]]},"published":{"date-parts":[[2019,4,26]]}}}